Da der kun findes få patienter med MPS VI, blev Naglazyme udpeget som "lægemiddel til sjældne sygdomme" den 14. februar 2001.
Because the number of patients with MPS VI is low, the disease is considered ‘ rare’, and Naglazyme was designated an ‘ orphan medicine ’ (a medicine used in rare diseases) on 14 February 2001.